Ruxolitinib tlrl rux

Manufactured by InvivoGen

Sourced in United States

Ruxolitinib (tlrl-rux) is a selective and potent Janus kinase (JAK) 1 and 2 inhibitor. It is a powder for in vitro use.

Automatically generated - may contain errors

Lab products found in correlation

Lipopolysaccharides (lps), by Merck Group (1 mentions) Mcc950, by Merck Group (1 mentions) Ro 31 8220, by Bio-Techne (1 mentions) Staurosporine s 9300, by LC Laboratories (1 mentions) Alvocidib, by Selleck Chemicals (1 mentions) Sunitinib, by Selleck Chemicals (1 mentions) Sml0543, by Merck Group (1 mentions)

Spelling variants of this product

Ruxolitinib (35 citations)

3 protocols using ruxolitinib tlrl rux

Hycanthone and LPS-Induced Inflammation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Hycanthone (Cat No. HY-B1099) was purchased from MedChemExpress (NJ, USA) and LPS (Cat No. L2630) was obtained from Sigma-Aldrich (MO, USA). Hycanthone (25 and 50 mg/kg) was dissolved in 0.1% dimethyl sulfoxide (DMSO) for in vitro assays, and in 10% DMSO plus 10% Tween 80 in saline solution for in vivo experiments. Mice were treated with hycanthone or vehicle using intraperitoneal injection. Ruxolitinib (tlrl-rux, InvivoGen, CA, USA) and MCC950 (PZ0280, Sigma-Aldrich) were obtained. Ruxolitinib was dissolved at 0.1 μM and MCC950 at 50 μM in culture media.

Boo K.J., Gonzales E.L., Remonde C.G., Seong J.Y., Jeon S.J., Park Y.M., Ham B.J, & Shin C.Y. (2022). Hycanthone Inhibits Inflammasome Activation and Neuroinflammation-Induced Depression-Like Behaviors in Mice. Biomolecules & Therapeutics, 31(2), 161-167.

+ Open protocol

+ Expand

Small Molecule Kinase Inhibitors Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Ruxolitinib (TLRL-Rux) was from Invivogen and baricitinib (HY-15315) was from MedChem Express (Mounmouth Junction, NJ, USA). Tofacitinib (S2789), entospletinib (S7523), upadacitinib (S8162) and oclacitinib (S8195) were from Selleck Chemicals (Houston, TX, USA). STAT5 inhibitor (15784) was from Cayman Chemical Company. PP2 (1407) and Ro 31–8220 (2002) were from Tocris (Bristol, UK).

Parra-Izquierdo I., Melrose A.R., Pang J., Lakshmanan H.H., Reitsma S.E., Vavilapalli S.H., Larson M.K., Shatzel J.J., McCarty O.J, & Aslan J.E. (2021). Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function. Platelets, 33(3), 404-415.

+ Open protocol

+ Expand

Nematode Intestinal Toxin Screening

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

A set of chemicals identified as nematode intestinal toxins/toxicants (NITs) [3 (link)] were used in experiments here and included: alvocidib (S1230), sunitinib (S7781), Selleckchem Houston, TX, USA; CID1067700 (SML054), leflunomide (L5025), p38 MAP kinase inhibitor IV (a.k.a. MT4, which was used in this paper, SML0543) Sigma-Aldrich, St. Louis, MO, USA; ruxolitinib (tlrl-rux), InvivoGen, San Diego, CA, USA; staurosporine (S-9300), LC Laboratories, Woburn, MA, USA. DMSO was used as diluent for chemical treatments, except propidium iodide was solubilized in PBS, and concentrations were adjusted to achieve a maximum 1% DMSO after all components were included for each experiment. Control wells were adjusted according to diluent used for treatment wells. With the exception of staurosporine, treatments were initiated at 500 μM (staurosporine, 25 μM) to better ensure the possibility of achieving a positive result with PI labeling based on previous experience [3 (link)]. Dose response experiments to determine effective dose 50 (IC₅₀) were conducted using two-fold serial dilutions over a range of 5 concentrations. IC₅₀ values were calculated using AAT Bioquest (Sunnyvale, CA, USA) IC₅₀ calculator (https://www.aatbio.com/tools/IC50-calculator/ (accessed on June 17 2021)).

Jasmer D.P., Rosa B.A, & Mitreva M. (2021). Cell Death and Transcriptional Responses Induced in Larvae of the Nematode Haemonchus contortus by Toxins/Toxicants with Broad Phylogenetic Efficacy. Pharmaceuticals, 14(7), 598.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!